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RNA processing is vital for the high ﬁdelity and diversity of eukaryotic transcriptomes and the
encoded proteomes. However, control of RNA processing is not fully established. R RNA is a class
of conserved large non-coding RNAs (murine Hepcarcin; human MALAT-1) up-regulated in carcino-
mas. Using antisense technology, we identiﬁed that RNA post-transcriptional modiﬁcation is the
most signiﬁcant global function ofR RNA. Speciﬁcally, processing of the pre-mRNAs of genes includ-
ing Tissue Factor and Endoglin was altered by hydrolysis of R RNA/MALAT-1. These results support
the hypothesis that R RNA/MALAT-1 is a regulatory molecule exerting roles in RNA post-transcrip-
tional modiﬁcation.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction vascular endothelium [5], over-expressed in metastatic non-smallTranscription of eukaryotic genes generatespre-mRNAtranscripts
that are processed tomaturemRNAs through various post-transcrip-
tional modiﬁcations including capping, splicing, polyadenylation,
degradation, andnuclear exportation. This is vital for the high ﬁdelity
anddiversity of eukaryotic transcriptomes,where deregulation of the
process is associated with diverse diseases such as cancer [1]. RNA-
binding proteins including the serine/arginine rich (SR) proteins and
heterogeneous nuclear ribonucleoproteins (hnRNPs) play key roles
in RNA splicing and degradation [2,3]. Interestingly, SR proteins and
hnRNPs can be alternatively spliced themselves [4]. Despite these
reasonablywell-documentedcomponents andregulationofRNApro-
cessing by proteins, upstream control of RNA processing, particularly
by RNA, has yet to be adequately elucidated.
Hepcarcin [5] and its human orthologue Alpha transcript (i.e.,
MALAT-1 or NEAT2) [6–8] are large non-coding RNAs (ncRNAs).
In recognition that they are orthologous and the human ortholog
is functional, as identiﬁed in this and other studies [9,10], we have
proposed the term R RNA to categorize them as a novel functional
group of RNA. R RNA/MALAT-1 is selectively expressed in tumorchemical Societies. Published by E
; ENGalt, alternatively spliced
protein; IPA, ingenuity path-
; SR protein, serine/arginine-
tse@scripps.edu (T.S. Edging-cell lung carcinomas [6], up-regulated in six types of human carci-
nomas [5] and EpH4 cells transformed with the ErbB2 oncoprotein
[11]. Interestingly, recent studies suggested that inhibition of MA-
LAT-1 suppressed proliferation and invasion of CaSki cervical can-
cer cells [9] and impaired mobility of cancer cells [10], consistent
with over-expression of MALAT-1 in cancer and its importance in
cancer biology. In human Tig1 cells, R RNA/MALAT-1 associates
with SC35 domains containing molecules including SR proteins
that are involved in pre-mRNA modiﬁcation [8]. These observa-
tions support the hypothesis that R RNA/MALAT-1 inﬂuences
RNA processing.
Using antisense oligonucleotides (ASOs) as a tool to selectively
mediate hydrolysis of R RNA/MALAT-1 in HeLa cells and HUVECs,
this study supports the hypothesis that human R RNA/MALAT-1
may be a global regulator of RNA post-transcriptional modiﬁcation.
Processing of the pre-mRNAs of genes encoding Tissue Factor and
Endoglin (ENG) that play important roles in cancer biology is al-
tered by hydrolysis of R RNA/MALAT-1. These observations indi-
cate that R RNA/MALAT-1 is a large ncRNAs functioning as a
regulator of RNA processing in higher eukaryotic cells.
2. Materials and methods
2.1. Cells and reagents
Cells were originally obtained from the American Type Tissue
Collection. HeLa cells were cultured in DMEM supplemented withlsevier B.V. All rights reserved.
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37 C. HUVECs were maintained in EGM medium and supple-
mented with 2% FCS (Lonza) in a humidiﬁed 5% CO2 incubator at
37 C.
2.2. ASO synthesis and transfection
Antisense phosphorothioate oligonucleotides modiﬁed with 20-
methoxyethyl were synthesized as described [12]. Unless other-
wise indicated, transfection with ASOs were performed using
Opti-MEM (Invitrogen) containing 75 nM of ASOs and 2.25 lg/ml
Lipofectin (Invitrogen, or 1 lg/ml Lipofectamine 2000 for HUVECs)
at 37 C for 4 h, at which time the medium was replaced with stan-
dard growth medium. Untreated control (UTC) or scrambled ASO
(Con) at 75 nM were used as negative controls. The sequences of
R RNA/MALAT-1 speciﬁc ASOs and their targeted regions are given
in the Supplementary Table S1.
2.3. RNA isolation, Northern analyses, RT-PCR, and quantitative PCR
RNAs were isolated using RNeasy methodology (Qiagen).
Northern blot analyses were performed as described [5]. Unless
otherwise indicated, the probe for human R RNA/MALAT-1 recog-
nizes nucleotide (nt) 3581–4585 of EF177381. The probes for ENG
recognize nt 881–1292 or nt 881–1070 of NM_000118.1. The probe
for TF recognize nt 544–1125of F3 (NM_001993), the gene encoding
TF. cDNAs used for RT-PCR or quantitative PCRwere generated with
QuantiTect Reverse Transcription Kit (Qiagen). For RT-PCR analyses
of TF transcripts, primers were designed according to the sequences
of NM_001993 to amplify the region between exon 4 and 6 (nt
600–1183) of F3. The primers (IDT Technologies) were forward pri-
mer, 50-ggacagccaacaattcagag-30; reverse primer, 50-tccagggtctt-
catgctcc-30. The RT-PCR products were resolved on 1.2% agarose
gels. Quantitative PCR for GAPDH and R RNA/MALAT-1 were per-
formed using Taqman universal PCR mix and Taqman gene expres-
sion assay mix that included FAM-dye labeled MGB probes
(Applied Biosystems). Taqman gene expression assay mixes were
Hs99999905_m1forhumanGAPDH,andHs00273907_s1 forhuman
R RNA/MALAT-1, respectively (Applied Biosystems). The primers
speciﬁcally detecting hTFalt were forward, exon 4–6 junction pri-
mer, 50-caagttcaggaaagaaatattctac-30; reverse primer, 50-gaaacatt-
cagtggggagttctcc-30; and probe, 50-[6-FAM]catccttgtcatcatcctggcta
tatc[TAMRA-6-FAM]. The qPCR primers for full length TF were for-
ward primer, 50-caggctggagtgcagtagca-30; reverse primer, 50-aggct-
gaggcagacaattgc-30; and probe, 50-[6-FAM]cttgcaccctccgtctctcggg
[TAMRA-6-FAM].
2.4. Affymetrix exon array and ingenuity pathway analysis (IPA)
Sixteen paired samples of total RNAs from cells transfected with
control ASO (Con) or human R RNA/MALAT-1 speciﬁc ASOs (75 nM
ASO254 for HeLa cells, or a mixture of 25 nM ASO254, ASO240, and
ASO280 for HUVECs) were harvested 24 h after transfection. Total
RNAs (2 lg) were depleted more than 95% of rRNAs using
Ribominus (Invitrogen), and synthesized to double-stranded cDNA
using random hexamers tagged with a T7 promoter sequence.
Antisense cRNAs were generated from the cDNAs using T7 RNA
polymerase, and used to generate single-strandedDNAs in the sense
orientation using GeneChip Whole Transcript (WT) Sense Target
Labeling Assay (Affymetrix). The single-stranded DNAs were frag-
mented and terminal-labeled with biotin, and hybridized to 16
GeneChip Human Exon 1.0 ST Arrays (Affymetrix). Gene chips were
washed, stained using Genechip Fluidics Station 450 (Affymetrix)
and Genechip Operating Software (GCOS), and scanned using Gene-
chip Scanner 3000 7G (Affymetrix). The data were analyzed using
XRAY (version 2.63) software, the Excel add-in from BiotiqueSystems Inc. The differentially expressed transcripts were uploaded
to IPA (Ingenuity Systems, RedwoodCity, CA) for functional analysis.
2.5. Western blot analysis
HUVECs were grown to 90% conﬂuency. Total proteins were
isolated by resuspending cells in 2X SDS reducing buffer followed
by sonication to lyse the cells completely. Equal amounts of cell
lysates were run on 8–16% gradient reducing gels (Invitrogen)
and transferred by voltage gradient to positively charged nitrocel-
lulose membranes in 20 min. The membranes were washed in 1X
TBST (Tris-Buffered Saline Tween-20) buffer and incubated with
10% milk (blocking agent) at 4 C overnight. The membranes were
incubated with polyclonal antibodies S2945 (Sigma), ab38813
(Abcam), and A2066 (Sigma) to detect SFRS12, SFRS1, and actin
proteins, respectively, for 30 min with agitation and washed three
times with 1X TBST. The membranes were then incubated with
HRP-conjugated goat anti-rabbit antibody (Pierce) diluted 1:1000
with milk for 30 min with agitation and then washed four times
with 1X TBST buffer. The membranes were developed with Super-
Signal West Femto Chemiluminescent Substrate (Pierce); the sig-
nals were developed by exposure to HyBlot CL ﬁlms (Denville)
and quantiﬁed with Scion Image software.
3. Results and discussion
3.1. Regulation of post-transcriptional modiﬁcation by R RNA/MALAT-1
Antisense technology was applied to characterize the functional
biology of R RNA/MALAT-1. R RNA/MALAT-1 was profoundly
reduced 24 h after transfection with ASOs speciﬁcally targeted to
the ncRNA in HeLa cells, with up to 100-fold target reduction by
Northern and densitometric analyses using ASO254 and quantita-
tive RT-PCR analysis (Fig. 1A and data not shown). Based on its
predominant nuclear localization and association with SC35 splic-
ing domains [5,8], we used Affymetrix exon arrays, which permit
proﬁling of transcript architecture and evaluation of splicing, to
explore transcripts that were differentially expressed and spliced
after profound reduction of R RNA/MALAT-1. RNAs were harvested
from HeLa cells 24 h after transfection with control ASO or
ASO254, selected based on the highest speciﬁc target reduction
(Fig. 1A), and processed for array analysis. Using P < 0.001 as cut-
off in the global analysis of the array data, 276 genes exhibited
highly signiﬁcant alternative splicing differences between
ASO254 transfectants and the control (Table S2). IPA of the 276
genes indicated that RNA post-transcriptional modiﬁcation was
the function most signiﬁcantly affected by reduction of R RNA/
MALAT-1 by ASO254 (P < 1.2  108, Fig. 1B). The molecules in this
functional category and their interaction network are shown in
Fig. 1C, many of which are SR proteins (SFRS1, SFRS6, and SFRS12)
that play important roles in mRNA metabolism such as constitu-
tive and alternative splicing, RNA stability, and mRNA quality
control [2]. Also included in the network are hnRNP proteins
(HNRNPU, HNRNPA2B1, and HNRPK) that participate in mRNA
biogenesis. In cultured human umbilical vein endothelial cells
(HUVECs), 668 genes exhibited alternative splicing differences
(P < 0.001, Table S3) 24 h after transfection with ASOs targeted to
R RNA/MALAT-1. RNA post-transcriptional modiﬁcation was also
the most signiﬁcant function (P < 6.8  109, Fig. S1) affected by
reduction of R RNA/MALAT-1, which included transcripts of SR
proteins SFRS1, SFRS6, SFRS8, and SFRS21P (Table S3). These
results are consistent with a prior report that all SR proteins
analyzed were alternatively spliced [13]. Collectively, these data
support that human R RNA/MALAT-1 inﬂuences the alternative
splicing activity of a broad spectrum of molecules that are
involved in RNA processing.
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Fig. 1. Evidence that R RNA/MALAT-1 regulates RNA post-transcriptional modiﬁcation globally in HeLa cells. (A) Target reduction of R RNA/MALAT-1 by ASOs. RNAs from
HeLa cell transfectants were used for Northern analyses. Position of R RNA/MALAT-1 is indicated. GAPDH, loading controls. UTC, untreated control; Con, scrambled ASO; 240,
254, and 280,R RNA/MALAT-1 speciﬁc ASOs. (B) IPA analyses of genes whose alternative splicing activity were signiﬁcantly changed (P < 0.001) byR RNA/MALAT-1 reduction
in HeLa cells. (C) Components of the top class of differentially expressed genes and their network. Bold, transcripts of SR proteins. Red and green, up- and down- regulated
transcripts, respectively, in the ASO254-transfected HeLa cells with signiﬁcantly changed alternative splicing activity (P < 0.001) due to R RNA/MALAT-1 reduction.
Uncolored, genes in the network that were not identiﬁed in the exon array analysis.
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To conﬁrm the regulation of SR proteins byR RNA/MALAT-1, we
analyzed the expression of SFRS12 and SFRS1 in HUVECs upon sup-
pression of R RNA/MALAT-1. Transfection of ASO254 resulted in a
signiﬁcant increase (P < 0.05) of protein level of the major isoform
(59.4 kDa) of SFRS12 (Fig. 2A), but not the minor isoform
(71.6 kDa) of SFRS12 (data not shown), consistent with a hypothe-
sis that perturbation of presence or levels of R RNA/MALAT-1 af-
fects alternative splicing of SFRS12 mRNA and hence the encoded
protein products. Additionally, transfection of ASO254 enhanced
expression of SFRS1 protein in HUVECs (Fig. 2B). Collectively, the
above data support the hypothesis that perturbation ofR RNA/MA-
LAT-1 with ASO254 changed expression of SR proteins SFSR12 and
SFRS1, consistent with regulation by R RNA/MALAT-1 of RNA post-
transcriptional modiﬁcation.
3.3. Alteration of ENG transcripts by R RNA/MALAT-1
In addition to genes involved in RNA post-transcriptional mod-
iﬁcation, processing of other gene transcripts was also affected by
R RNA/MALAT-1 suppression. One of the genes of interest was
human Endoglin that encodes a homodimeric membrane glycopro-
tein [14] that is elevated in activated endothelial cells and solidtumors [15]. Numerous alternatively spliced Endoglin (ENGalt)
transcripts have been identiﬁed in health and disease [16]. North-
ern analyses with an antisense probe targeting nt 881–1292 of the
3.1-kb canonical ENG mRNA (GenBank accession # NM_000118.1)
demonstrated expression in HeLa cells (Fig. 3A). Interestingly, an
1.8-kb transcript was observed in HeLa cells and HUVECs follow-
ing R RNA/MALAT-1 suppression by ASO254 (ENGalt, Fig. 3A and
B), but barely detected in the control cells, consistent with the
requirement of R RNA/MALAT-1 suppression for generating the
ENGalt transcript.
3.4. Regulation of Tissue Factor transcript repertoire by R RNA/
MALAT-1
Tissue Factor (TF) was another transcript identiﬁed in our
microarray analysis with altered RNA processing after knockdown
of R RNA/MALAT-1. TF plays important roles in tumor growth,
angiogenesis, and metastasis [17]. Two forms of alternative splic-
ing events exist for human TF mRNA, i.e., intron 1 retained (e.g.,
AY940729, Fig. S2) and exon 5 skipped (e.g., AF497569). Twenty-
four hours following transfection, R RNA/MALAT-1 was markedly
diminished in HeLa cells transfected with ASO254 (Fig. 4A). In
addition to the major 2.2-kb form of mature TF, two minor
3-kb transcripts, iTF, were observed, consistent with previous
SFRS1
actin
Con ASO254
A
B
Fig. 2. Evidence that R RNA/MALAT-1 regulates SR proteins in HUVECs. Cells were transfected withR RNA/MALAT-1 ASO254 or control ASO. Proteins from 24 h transfectants
were used for Western blot analysis. (A) Quantiﬁcation of the expression levels of the 59.4 kDa major isoform of SFRS12 protein. (B) Images and quantiﬁcation of the
expression levels of the 27.7 kDa isoform of SFRS1. Actin immunoblotting was used as protein loading control.
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Fig. 3. Evidence that R RNA/MALAT-1 regulates processing of Endoglin transcript.
Twenty-four hours after transfection with 75 nM ASOs, total RNAs were harvested
from cells. Northern blot analyses of RNAs from HeLa (A) and HUVECs (B) are
shown. UTC, untreated control; Con, scrambled ASO; 254, R RNA/MALAT-1 speciﬁc
ASO. GAPDH, loading controls.
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2.2-kb TF transcript, were identiﬁed with a probe for intron 1 of
F3 (data not shown). The iTF transcripts were signiﬁcantly de-
creased (P < 0.005) in the ASO254 transfected cells compared with
the control (Fig. 4A), with an 2-fold difference (Fig. 4B). Interest-
ingly, the mature TF transcript also appeared to be decreased in the
ASO254 transfected cells (Fig. 4A). These results suggest that R
RNA/MALAT-1 inﬂuences TF transcript repertoire.
Both TF and TFalt are induced in endothelial cells by endotoxin
[19] or inﬂammatory responses [20]. To address the role of R RNA/
MALAT-1 in control of TF alternative splicing in endothelial cells,HUVEC were transfected with R RNA/MALAT-1 ASO254, then ex-
posed to 10 lg/ml LPS for 4 h before harvesting RNA. R RNA/MA-
LAT-1 was signiﬁcantly reduced 24 h after transfection with
ASO254 (Fig. 5A), with an average eightfold target reduction.
Semi-quantitative RT-PCRs detected both full-length TF and exon
5 skipped hTFalt in the LPS-treated cells. The amount of hTFalt
transcript was signiﬁcantly elevated in the R RNA/MALAT-1 sup-
pressed cells (Fig. 5A and B). Quantitative PCR (qPCR) using prim-
ers speciﬁc to hTFalt indicated an 2.5-fold increase of the exon 5
skipped hTFalt transcript byR RNA/MALAT-1 suppression (Fig. 5C).
The speciﬁcity of the qPCR was conﬁrmed by the appearance of a
single band of qPCR product, and subsequent sequencing of this
DNA band extracted from the agarose gel (data not shown). Collec-
tively, these results indicate that R RNA/MALAT-1 inﬂuences the
generation of alternatively spliced TF transcripts and thereby
may inﬂuence the coagulation and cellular signaling pathways.
In summary, the present study has identiﬁed that human R
RNA/MALAT-1 modulates the transcript repertoire as a result of
post-transcriptional modiﬁcations of primary transcripts. This
follows from consideration of two scenarios. In a global view,
RNA post-transcriptional modiﬁcation is the most signiﬁcant
function inﬂuenced by reduction of R RNA/MALAT-1. With spe-
ciﬁc examples, we provide evidence for the controlling function
of R RNA/MALAT-1 on primary transcript modiﬁcation, i.e., ENG
and Tissue Factor that both play roles in tumor biology [15,17].
Perturbation of R RNA/MALAT-1 altered splicing activity of genes
that encode SR proteins and hnRNPs, which themselves partici-
pate in RNA processing. Collectively, these results are consistent
with a hypothesis that R RNA/MALAT-1 is a master regulator of
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Fig. 4. Retention of intron 1 sequences in TF mRNA and the involvement of R RNA/MALAT-1. HeLa cells were transfected with 75 nM ASO254 against R RNA/MALAT-1 or
control ASO. Twenty-four hours after transfection, total RNAs were harvested. (A) Northern analyses. UTC, untreated control. Top panels show knockdown of R RNA/MALAT-1
by ASO254. Middle panels show three distinguished bands of TF transcripts, a major 2.2-kb (TF) and two minor 3-kb forms (iTF). Bottom panels show GAPDH as loading
controls. Molecular size markers are shown to the right. (B) Quantitative results of iTF (both forms) based on Northern analyses normalized with GAPDH levels, mean ± S.D.,
from three independent experiments.
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Fig. 5. Involvement of R RNA/MALAT-1 in TF alternative splicing in LPS-treated HUVEC. HUVEC were transfected with 75 nM ASO254 against R RNA/MALAT-1 or control ASO
for 24 h, and treated with 10 lg/ml LPS for 4 h. (A) Northern analyses (middle for R RNA/MALAT-1, and bottom for GAPDH), or RT-PCR for exons 4–6 of F3 (top). Molecular
size markers are shown to the right. (B) Quantitative results of the ratio of hTFalt/GAPDH transcripts, mean ± S.D., based on the RT-PCR results. (C) Ratio of hTFalt/GAPDH
transcripts based on qPCR results, mean ± S.D.
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MALAT-1 modiﬁes processing of a wide variety of transcripts
including the ones encoding SR proteins, phosphorylation of
which is also shown to be modulated by the ncRNA [21], and TF
and ENG that play important roles in tumor biology.
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